ПЕРВИЧНАЯ ДВУСТОРОННЯЯ МАКРОНОДУЛЯРНАЯ ГИПЕРПЛАЗИЯ НАДПОЧЕЧНИКОВ (ОБЗОР ЛИТЕРАТУРЫ)

УДК 616.43

DOI: 10.22138/2500-0918-2018-15-3-432-454

Т.П. Киселева, Т.Р. Чжен

Уральский государственный медицинский университет, г. Екатеринбург, Российская Федерация

Резюме. Актуальность. Клиническая значимость АКТГ — независимой формы гиперкортицизма, также известной как первичная двусторонняя макронодулярная гиперплазия надпочечников (ПДМГН), была подтверждена многочисленными исследованиями, показавшими метаболические последствия хронической гиперсекреции кортизола (ожирение, нарушение углеводного обмена, дислипидемия, артериальная гипертензия). В последние годы обнаружена эктопическая или аберрантная экспрессия рецепторов гормона в G-белках в коре надпочечников: глюкозозависимого инсулинотропного полипептида (ГИП), вазопрессина, бета-адренергические, лютеинизирующий гормон / человеческий хорионический гонадотропин (ЛГ / ХГЧ) — рецепторы и серотониновые рецепторы, а также рецепторы ангиотензина, лептина, глюкагона, ИЛ-1 и TТГ. Описаны мутации гена ARMC5, расположенном в 16p11.2. Цель. Рассмотрение современных методов патогенеза, диагностики и лечения ПДМГН с СК и без него, определение перспективных направлений работы. Материалы и методы. Поиск литературы с поисковым термином: «ПДМГН, АКТГ — независимый гиперкортицизм, ARMC5 ген». Источник: PubMed, Medline. Результаты. Обзор 174 просмотренных публикаций, 5% пациентов имели первичную гиперплазию надпочечников). Выводы. Изучить влияние ПДМГН, ее новые возможности в лечении пациентов.

Ключевые слова: первичная двусторонняя макронодулярная гиперплазия надпочечников (ПДМГН), аберрантные рецепторы, гиперкортицизм, ген ARMC5

Дата поступления 02.02.2018

Образец цитирования:
Киселева Т.П., Чжен Т.Р. Первичная двусторонняя гиперплазия надпочечников (Обзор литературы). Вестник уральской медицинской академической науки. 2018, Том 15, №3, с. 432–454, DOI: 10.22138/2500-0918-2018-15-3-432-454

ЛИТЕРАТУРА
1. Lieberman SA, Eccleshall TR, Feldman D: ACTH-independent massive bilateral adrenal disease (AIMBAD): A subtype of Cushing’s syndrome with major diagnostic and therapeutic implications. Eur J Endocrinol 1994;131:67–73. doi: 10.1530/eje.0/1310067
2. Lacroix A. ACTH-independent macronodular adrenal hyperplasia. Best Pract Res Clin Endocrinol Metab. 2009;23:245–259. http://dx.doi.org/10.1016/j.beem.2008.10.011 [PubMed]
3. Bourdeau I, Stratakis CA. Cyclic AMP-dependent signaling aberrations in macronodular adrenal disease. Ann NY Acad Sci. 2002;968:240–255. doi: 10.1111/j.1749-6632.2002.tb04339.x [PubMed]
4. Swain JM, Grant CS, Schlinkert RT, Thompson GB, van Heerden JA, Lloyd RV, Young WF: Corticotropin-independent macronodular adrenal hyperplasia: A clinicopathologic correlation. Arch Surg 1998;133:541–545. doi: 10.1001/archsurg.133.5.541
5. Hsiao HP, Kirschner LS, Bourdeau I, et al. Clinical and genetic heterogeneity, overlap with other tumor syndromes, and atypical glucocorticoid hormone secretion in adrenocorticotropin-independent macronodular adrenal hyperplasia compared with other adrenocortical tumors. J Clin Endocrinol Metab. 2009;94:2930–2937. doi: 10.1210/jc.2009-0516. [PMC free article] [PubMed] [Cross Ref]
6. Kirschner MA, Powell RD Jr, Lipsett MB: Cushing’s syndrome: Nodular cortical hyperplasia of adrenal glands with clinical and pathological features suggesting adrenocortical tumor. J Clin Endocrinol Metab 1964;24:947– 955. doi:10.1210/jcem-24-10-947
7. Christopoulos S, Bourdeau I, Lacroix A. Clinical and subclinical ACTH-independent macronodular adrenal hyperplasia and aberrant hormone receptors. Horm Res. 2005;64(3):119–131. doi: 10.1159/000088818 [PubMed]
8. Stratakis CA, Kirschner LS: Clinical and genetic analysis of primary bilateral adrenal diseases (micro- and macronodular disease) leading to Cushing syndrome. Horm Metab Res 1998;30:456–463. doi: 10.1055/s-2007-978914
9. Malchoff CD, MacGillivray D, Malchoff DM: Adrenocorticotropic hormone-independent adrenal hyperplasia. Endocrinologist. 6(2):79-85, March 1996.
10. Zeiger MA, Nieman LK, Cutler GB, Chrousos GP, Doppman JL, Travis WD, Norton JA: Primary bilateral adrenocortical causes of Cushing’s syndrome. Surgery. 1991;110(6):1106 — 1115.
11. Aiba M, Hirayama A, Iri H, Ito Y, Fujimoto Y, Mabuchi G, Murai M, Tazaki H, Maruyama H, Saruta T: Adrenocorticotropic hormone-independent bilateral adrenocortical macronodular hyperplasia as a distinct subtype of Cushing’s syndrome. Enzyme histochemical and ultrastructural study of four cases with a review of the literature. Am J Clin Pathol 1991 Sep; 96(3):334–340.
12. Lacroix A, N’Diaye N, Tremblay J, Hamet P: Ectopic and abnormal hormone receptors in adrenal Cushing’s syndrome. Endocr Rev 2001 Feb;22(1):75–110. doi: 10.1210/edrv.22.1.0420
13. Sijmons RH. Encyclopaedia of tumour-associated familial disorders. Part I: from AIMAH to CHIME syndrome. Hered Cancer Clin Pract. 2008 Feb 15;6(1):22–57. doi: 10.1186/1897-4287-6-1-22. [PMC free article] [PubMed]
14. Groussin L, Jullian E, Perlemoine K, et al. Mutations of the PRKAR1A gene in Cushing's syndrome due to sporadic primary pigmented nodular adrenocortical disease. J Clin Endocrinol Metab. 2002 Sep;87(9):4324–4329. doi: 10.1210/jc.2002-020592 [PubMed]
15. Horvath A, Boikos S, Giatzakis C, et al. A genome-wide scan identifies mutations in the gene encoding phosphodiesterase 11A4 (PDE11A) in individuals with adrenocortical hyperplasia. Nat Genet. 2006 Jul;38(7):794–800. doi: 10.1038/ng1809 [PubMed]
16. Minami S, Sugihara H, Sato J, Tatsukuchi A, Sugisaki Y, Sasano H, Wakabayashi I: ACTH independent Cushing’s syndrome occurring in siblings. Clin Endocrinol (Oxf) 1996 Apr;44(4):483–488. doi: 10.1046/j.1365-2265.1996.682504.x
17. Nies C, Bartsch DK, Ehlenz K, Wild A, Langer P, Fleischhacker S, Rothmund M: Familial ACTH-independent Cushing’s syndrome with bilateral macronodular adrenal hyperplasia clinically affecting only female family members. Exp Clin Endocrinol Diabetes 2002 Sep;110(6):277–283. doi: 10.1055/s-2002-34590
18. Findlay JC, Sheeler LR, Engeland WC, Aron DC: Familial adrenocorticotropin-independent Cushing’s syndrome with bilateral macronodular adrenal hyperplasia. J Clin Endocrinol Metab 1993 Jan;76(1):189–191.doi: 10.1210/jcem.76.1.8380604
19. Imohl M, Koditz R, Stachon A, Muller KM, Nicolas V, Pfeilschifter J, Krieg M: Catecholamine-dependent hereditary Cushing’s syndrome – Follow-up after unilateral adrenalectomy (in German). Med Klin (Munich) 2002 Dec 15;97(12):747–753.
20. Lee S, Jun S, Hong SW, Kim DJ, Rhee Y, Lim SK: Familial adrenocorticotropin-independent macronodular adrenal hyperplasia: Ectopic expression of vasopressin V1b, V2 receptors in the adrenal gland (abstract). 86th Meeting of the Endocrine Society, New Orleans, 2004, p 566.
21. Stratakis CA, Kirschner LS, Carney JA. Clinical and molecular features of the Carney complex: diagnostic criteria and recommendations for patient evaluation. J Clin Endocrinol Metab. 2001 Sep;86(9):4041–4046. doiI: 10.1210/jcem.86.9.7903 [PubMed]
22. Vezzosi D, Cartier D, Regnier C, et al. Familial adrenocorticotropin-independent macronodular adrenal hyperplasia with aberrant serotonin and vasopressin adrenal receptors. Eur J Endocrinol. 2007 Jan;156(3):21–31. doi: 10.1530/eje.1.02324. [PubMed] [Cross Ref]
23. Miyamura N, Taguchi T, Murata Y, et al. Inherited adrenocorticotropin-independent macronodular adrenal hyperplasia with abnormal cortisol secretion by vasopressin and catecholamines: detection of the aberrant hormone receptors on adrenal gland. Endocrine. 2002 Dec;19(3):319–326. doi: 10.1385/ENDO:19:3:319 [PubMed]
24. Matyakhina L, Freedman RJ, Bourdeau I, et al. Hereditary leiomyomatosis associated with bilateral, massive, macronodular adrenocortical disease and atypical cushing syndrome: a clinical and molecular genetic investigation. J Clin Endocrinol Metab. 2005 Jun;90(6):3773–3779. doi: 10.1210/jc.2004-2377 [PubMed]
25. Marchesa P, Fazio VW, Church JM, McGannon E. Adrenal masses in patients with familial adenomatous polyposis. Dis Colon Rectum. 1997 Sep;40(9):1023–1028. doi: 10.1007/BF02050923 [PubMed]
26. Beuschlein F, Reincke M, Karl M, et al. Clonal composition of human adrenocortical neoplasms. Cancer Res. 1994 Sep;54(18):4927–4932. [PubMed]
27. Gicquel C, Leblond-Francillard M, Bertagna X, et al. Clonal analysis of human adrenocortical carcinomas and secreting adenomas. Clin Endocrinol (Oxf) 1994 Apr;40(4):465–477. doi: 10.1111/j.1365-2265.1994.tb02485.x [PubMed]
28. Louiset E, Duparc C, Young J, et al. Intraadrenal corticotropin in bilateral macronodular adrenal hyperplasia. N Engl J Med. 2013 Nov;369:2115–2125. doi: 10.1056/NEJMoa1215245 [PubMed]
29. Lacroix A. Heredity and cortisol regulation in bilateral macronodular adrenal hyperplasia. N Engl J Med. 2013 Nov 28;369(22):2147–2149. doi: 10.1056/NEJMe1312792 [PubMed]
30. Smals AG, Pieters GF, van Haelst UJ, Kloppenborg PW: Macronodular adrenocortical hyperplasia in long-standing Cushing’s disease. J Clin Endocrinol Metab 1984 Jan;58(1):25–31. doi: 10.1210/jcem-58-1-25
31. Doppman JL, Miller DL, Dwyer AJ, Loughlin T, Nieman L, Cutler GB, Chrousos GP, Oldfield E, Loriaux DL: Macronodular adrenal hyperplasia in Cushing disease. Radiology 1988 Feb;166(2):347–352. doi: 10.1148/radiology.166.2.2827231
32. Hermus AR, Pieters GF, Smals AG, Pesman GJ, Lamberts SW, Benraad TJ, van Haelst UJ, Kloppenborg PW: Transition from pituitary-dependent to adrenal-dependent Cushing’s syndrome. N Engl J Med 1988 Apr 14;318(15):966–970. doi:10.1056/NEJM198804143181506
33. Sturrock ND, Morgan L, Jeffcoate WJ: Autonomous nodular hyperplasia of the adrenal cortex: Tertiary hypercortisolism? Clin Endocrinol (Oxf) 1995 Dec;43(6):753–758. doi: 10.1111/j.1365-2265.1995.tb00546.x
34. Hocher B, Bahr V, Dorfmuller S, Oelkers W: Hypercortisolism with non-pigmented micronodular adrenal hyperplasia: Transition from pituitary-dependent to adrenal-dependent Cushing’s syndrome. Acta Endocrinol (Copenh) 1993 Fab;128(2):120–125.
35. Choi Y, Werk EE, Jr., Sholiton LJ: Cushing’s syndrome with dual pituitary-adrenal control. Arch Intern Med 1970 Jun;125(6):1045–1049. doi:10.1001/archinte.1970.00310060123016
36. Aron DC, Findling JW, Fitzgerald PA, Brooks RM, Fisher FE, Forsham PH, Tyrrell JB: Pituitary ACTH dependency of nodular adrenal hyperplasia in Cushing’s syndrome. Report of two cases and review of the literature. Am J Med 1981 Aug ;71(2):302–306. doi: https://doi.org/10.1016/0002-9343(81)90132-7
37. Cheitlin RA, Westphal M, Cabrera CM, Fujii DK, Snyder J, Fitzgerald PA: Cushing’s syndrome due to bilateral adrenal macronodular hyperplasia with undetectable ACTH: Cell culture of adenoma cells on extracellular matrix. Horm Res 1988;29(4):162–167. doi: 10.1159/000180995
38. Sasano H, Suzuki T, Nagura H: ACTH-independent macronodular adrenocortical hyperplasia: Immunohistochemical and in situ hybridization studies of steroidogenic enzymes. Mod Pathol 1994 Feb;7(2):215–219.
39. Wada N, Kubo M, Kijima H, Ishizuka T, Saeki T, Koike T, Sasano H: Adrenocorticotropin-independent bilateral macronodular adrenocortical hyperplasia: Immunohistochemical studies of steroidogenic enzymes and post-operative course in two men. Eur J Endocrinol 1996 May;134(5):583–587. doi: 10.1530/eje.0.1340583
40. Sasano H: Localization of steroidogenic enzymes in adrenal cortex and its disorders. Endocr J 1994 Oct;41(5):471–482. doi: https://doi.org/10.1507/endocrj.41.471
41. Bourdeau I, Antonini S, Lacroix A, Kirschner LS, Lorang D, Libutti SK, Stratakis CA: Gene array analysis of macronodular adrenal hyperplasia confirms clinical heterogeneity and identifies several genes as molecular mediators. Oncogene 2004;26:1575–1585. doi: 10.1038/sj.onc.1207277. [PubMed] [Cross Ref]
42. Bourdeau I, D’Amour P, Hamet P, Boutin J-M, Lacroix A: Aberrant membrane hormone receptors in incidentally discovered bilateral macronodular adrenal hyperplasia with subclinical Cushing’s syndrome. J Clin Endocrinol Metab 2001 Nov;86(11):5534–5540. doi: 10.1210/jcem.86.11.8062
43. Lacroix A, Bourdeau I, Lampron A, Mazzuco TL, Tremblay J, Hamet P. Aberrant G-protein coupled receptor expression in relation to adrenocortical overfunction. Clin Endocrinol (Oxf). 2010 Jul;73(1):1–15. doi: 10.1111/j.1365-2265.2009.03689.x [PubMed]
44. Lacroix A, Bolte E, Tremblay J, Dupre J, Poitras P, Fournier H, Garon J, Garrel D, Bayard F, Taillefer R, Flanagan RJ, Hamet P: Gastric inhibitory polypeptide-dependent cortisol hypersecretion – A new cause of Cushing’s syndrome. N Engl J Med 1992;327:974–980. doi: 10.1056/NEJM199210013271402.[PubMed] [Cross Ref]
45. Reznik Y, Allali-Zerah V, Chayvialle JA, Leroyer R, Leymarie P, Travert G, Lebrethon MC, Budi I, Balliere AM, Mahoudeau J: Food-dependent Cushing’s syndrome mediated by aberrant adrenal sensitivity to gastric inhibitory polypeptide. N Engl J Med 1992;327:981–986. doi: 10.1056/NEJM199210013271403. [PubMed] [Cross Ref]
46. Herder WW, Hofland LJ, Usdin TB, de Jong FH, Uitterlinden P, van Koetsveld P, Mezey E, Bonner TI, Bonjer HJ, Lamberts SW. Food-dependent Cushing’s syndrome resulting from abundant expression of gastric inhibitory polypeptide receptors in adrenal adenoma cells. J Clin Endocrinol Metab. 1996;81:3168–3172. doi: 10.1210/jc.81.9.3168. [PubMed] [Cross Ref]
47. Horiba N, Suda T, Aiba M, Naruse M, Nomura K, Imamura M, Demura H: Lysine vasopressin stimulation of cortisol secretion in patients with adrenocorticotropin-independent macronodular adrenal hyperplasia. J Clin Endocrinol Metab 1995;80:2336–2341. doi: 10.1210/jc.80.8.2336.[PubMed] [Cross Ref]
48. Lacroix A, Tremblay J, Touyz RM, Deng LY, Lariviere R, Cusson JR, Schiffrin EL, Hamet P: Abnormal adrenal and vascular responses to vasopressin mediated by a V1-vasopressin receptor in a patient with adrenocorticotropin-independent macronodular adrenal hyperplasia, Cushing’s syndrome, and orthostatic hypotension. J Clin Endocrinol Metab 1997;82:2414–2422. doi:10.1210/jc.82.8.2414. [PubMed] [Cross Ref]
49. Arnaldi G, Gasc JM, de Keyzer Y, Raffin-Sanson ML, Perraudin V, Kuhn JM, Raux-Demay MC, Luton JP, Clauser E, Bertagna X: Variable expression of the V1 vasopressin receptor modulates the phenotypic response of steroid-secreting adrenocortical tumors. J Clin Endocrinol Metab 1998 Jun;83(6):2029–2035. doi: 10.1210/jcem.83.6.4873
50. Cartier D, Lihrmann I, Parmentier F, Bastard C, Bertherat J, Caron P, Kuhn JM, Lacroix A, Tabarin A, Young J, Vaudry H, Lefebvre H: Overexpression of serotonin4 receptors in cisapride-responsive adrenocorticotropin-independent bilateral macronodular adrenal hyperplasia causing Cushing’s syndrome. J Clin Endocrinol Metab 2003;88:248–254. doi: 10.1210/jc.2002-021107. [PubMed][Cross Ref]
51. Lacroix A, Tremblay J, Rousseau G, Bouvier M, Hamet P: Propranolol therapy for ectopic beta-adrenergic receptors in adrenal Cushing’s syndrome. N Engl J Med 1997;337:1429–1434. doi: 10.1056/NEJM199711133372004. [PubMed] [Cross Ref]
52. Assie G, Louiset E, Sturm N, Rene-Corail F, Groussin L, Bertherat J, et al. Systematic analysis of G protein-coupled receptor gene expression in adrenocorticotropin-independent macronodular adrenocortical hyperplasia identifies novel targets for pharmacological control of adrenal Cushing’s syndrome. J Clin Endocrinol Metab (2010) 95:E253–62. doi:10.1210/jc.2009-2281 [PubMed] [Cross Ref]
53. Lacroix A, Hamet P, Boutin JM: Leuprolide acetate therapy in luteinizing hormone-dependent Cushing’s syndrome. N Engl J Med 1999;341:1577–1581. doi: 10.1056/NEJM199911183412104.[PubMed] [Cross Ref]
54. Feelders RA, Lamberts SW, Hofland LJ, van Koetsveld PM, Verhoef-Post M, Themmen AP, de Jong FH, Bonjer HJ, Clark AJ, van der Lely AJ, de Herder WW: Luteinizing hormone (LH)-responsive Cushing’s syndrome: The demonstration of LH receptor messenger ribonucleic acid in hyperplastic adrenal cells, which respond to chorionic gonadotropin and serotonin agonists in vitro. J Clin Endocrinol Metab 2003;88:230–237. doi: 10.1210/jc.2002-020621. [PubMed] [Cross Ref]
55. Mazzuco TL, Chabre O, Feige JJ, Thomas M. Aberrant expression of human luteinizing hormone receptor by adrenocortical cells is sufficient to provoke both hyperplasia and Cushing’s syndrome features. J Clin Endocrinol Metab. 2006;91:196–203. doi: 10.1210/jc.2005-1975. [PubMed][Cross Ref]
56. Nakamura Y, Son Y, Kohno Y, Shimono D, Kuwamura N, Koshiyama H, Sasano H, Matsuda T: Case of adrenocorticotropic hormone-independent macronodular adrenal hyperplasia with possible adrenal hypersensitivity to angiotensin II. Endocrine 2001;15:57–61. doi: 10.1385/ENDO:15:1:057.[PubMed] [Cross Ref]
57. Miguel V, Redal MA, Viale ML, Kahan M, Glerean M, Beskow A, Fainstein Day P. Aberrant expression of glucagon receptors in adrenal glands of a patient with Cushing’s syndrome and ACTH-independent macronodular adrenal hyperplasia. Medicina (B Aires) 2010;70(3):254–256. PMID: 20529775. [PubMed]
58. Libe R, Coste J, Guignat L, Tissier F, Lefebvre H, Barrande G, Ajzenberg C, Tauveron I, Clauser E, Dousset B. et al. Aberrant cortisol regulations in bilateral macronodular adrenal hyperplasia: a frequent finding in a prospective study of 32 patients with overt or subclinical Cushing’s syndrome. Eur J Endocrinol. 2010;163:129–138. doi: 10.1530/EJE-10-0195. [PubMed] [Cross Ref]
59. Schorr I, Ney RL: Abnormal hormone responses of an adrenocortical cancer adenyl cyclase. J Clin Invest 1971 Jun;50(6):1295–1300. doi: 10.1172/JCI106608
60. Kirk JM, Brain CE, Carson DJ, Hyde JC, Grant DB: Cushing’s syndrome caused by nodular adrenal hyperplasia in children with McCune-Albright syndrome. J Pediatr 1999;134:789–792.doi: https://doi.org/10.1016/S0022-3476(99)70302-1
61. Aarskog D, Tveteraas E: McCune-Albright’s syndrome following adrenalectomy for Cushing’s syndrome in infancy. J Pediatr 1968 Jul;73(1):89–96. https://doi.org/10.1016/S0022-3476(68)80043-5
62. Benjamin DR, McRoberts JW: Polyostotic fibrous dysplasia associated with Cushing syndrome. Arch Pathol 1973 Sep;96(3):175–178.
63. Mauras N, Blizzard RM: The McCune-Albright syndrome. Acta Endocrinol Suppl (Copenh) 1986;279:207–217.
64. Shenker A, Laue L, Kosugi S, Merendino JJJ, Minegishi T, Cutler GBJ: A constitutively activating mutation of the luteinizing hormone receptor in familial male precocious puberty. Nature 1993 Oct 14;365(6447):652–654. doi: 10.1038/365652a0
65. MacMahon HE: Albright’s syndrome – Thirty years later. (Polyostotic fibrous dysplasia). Pathol Annu 1971;6:81–146.
66. Danon M, Robboy SJ, Kim S, Scully R, Crawford JD: Cushing syndrome, sexual precocity, and polyostotic fibrous dysplasia (Albright syndrome) in infancy. J Pediatr 1975 Dec;87(6 Pt 1):917–921.doi: https://doi.org/10.1016/S0022-3476(75)80905-X
67. Hamet P, Larochelle P, Franks DJ, Cartier P, Bolte E: Cushing syndrome with food-dependent periodic hormonogenesis. Clin Invest Med 1987 Nov;10(6):530–533.
68. N’Diaye N, Hamet P, Tremblay J, Boutin JM, Gaboury L, Lacroix A: Asynchronous development of bilateral nodular adrenal hyperplasia in gastric inhibitory polypeptide-dependent Cushing’s syndrome. J Clin Endocrinol Metab 1999 Aug;84(8):2616–2622. doi: 10.1210/jcem.84.8.5930
69. Lebrethon MC, Avallet O, Reznik Y, Archambeaud F, Combes J, Usdin TB, Narboni G, Mahoudeau J, Saez JM: Food-dependent Cushing’s syndrome: Characterization and functional role of gastric inhibitory polypeptide receptor in the adrenals of three patients. J Clin Endocrinol Metab 1998 Dec;83(12):4514–4519. doi: 10.1210/jcem.83.12.5336
70. Pralong FP, Gomez F, Guillou L, Mosimann F, Franscella S, Gaillard RC: Food-dependent Cushing’s syndrome: Possible involvement of leptin in cortisol hypersecretion. J Clin Endocrinol Metab 1999 Oct;84(10):3817–3822. doi: 10.1210/jcem.84.10.6068
71. Gerl H, Rohde W, Biering H, Schulz N, Lochs H: Food-dependent Cushing syndrome of long standing with mild clinical features (in German). Dtsch Med Wochenschr 2000 Dec 22;125(51-52):1565–1568.doi: 10.1055/s-2000-9524
72. Groussin L, Perlemoine K, Contesse V, Lefebvre H, Tabarin A, Thieblot P, Schlienger JL, Luton JP, Bertagna X, Bertherat J: The ectopic expression of the gastric inhibitory polypeptide receptor is frequent in adrenocorticotropin-independent bilateral macronodular adrenal hyperplasia, but rare in unilateral tumors. J Clin Endocrinol Metab 2002 May;87(5):1980–1985. doi: 10.1210/jcem.87.5.8458
73. Croughs RJ, Zelissen PM, Van Vroonhoven ThJ, Hofland LJ, N’Diaye N, Lacroix A, de Herder WW: GIP-dependent adrenal Cushing’s syndrome with incomplete suppression of ACTH. Clin Endocrinol (Oxf) 2000 Feb;52(2):235–240. doi: 10.1046/j.1365-2265.2000.00932.x
74. Chabre O, Liakos P, Vivier J, Chaffanjon P, Labat-Moleur F, Martinie M, Bottari SP, Bachelot I, Chambaz EM, Defaye G, Feige JJ: Cushing’s syndrome due to a gastric inhibitory polypeptide-dependent adrenal adenoma: Insights into hormonal control of adrenocortical tumorigenesis. J Clin Endocrinol Metab 1998 Sep;83(9):3134–3143. doi: 10.1210/jcem.83.9.5140
75. Luton JP, Bertagna X: Membrane receptors and endocrine tumors: Expression of vasopressin receptor V1 modulates the pharmacologic phenotype of adrenocortical tumors (in French). Bull Acad Natl Med 1998;182(2):299–309.
76. Tsagarakis S, Tsigos C, Vassiliou V, Tsiotra P, Pratsinis H, Kletsas D, Trivizas P, Nikou A, Mavromatis T, Sotsiou F, Raptis S, Thalassinos N: Food-dependent androgen and cortisol secretion by a gastric inhibitory polypeptide-receptor expressive adrenocortical adenoma leading to hirsutism and subclinical Cushing’s syndrome: In vivo and in vitro studies. J Clin Endocrinol Metab 2001 Feb;86(2):583–589. doi: 10.1210/jcem.86.2.7171
77. N’Diaye N, Tremblay J, Hamet P, de Herder WW, Lacroix A: Adrenocortical overexpression of gastric inhibitory polypeptide receptor underlies food-dependent Cushing’s syndrome. J Clin Endocrinol Metab 1998 Aug;83(8):2781–2785. doi: 10.1210/jcem.83.8.5038
78. Longo-Mazzuco T, Chabre O, Feige JJ, Thomas M: Demonstration du potentiel transformant du gene du recepteur du GIP dans les cellules du cortex surrenalien: un pas vers l’etiologie du syndrome de Cushing lie a l’alimentation. Ann Endocrinol (Paris) 2004;65:267.
79. Mazzocchi G, Rebuffat P, Meneghelli V, et al. Gastric inhibitory polypeptide stimulates glucocorticoid secretion in rats, acting through specific receptors coupled with the adenylate cyclase-dependent signaling pathway. Peptides. 1999;20(5):589-594. https://doi.org/10.1016/S0196-9781(99)00011-X
80. Lee S, Jun S, Hong SW, Kim DJ, Rhee Y, Lim SK: Familial adrenocorticotropin-independent macronodular adrenal hyperplasia: Ectopic expression of vasopressin V1b, V2 receptors in the adrenal gland (abstract). 86th Meeting of the Endocrine Society, New Orleans, 2004, p 566.
81. Yamakita N, Murai T, Ito Y, Miura K, Ikeda T, Miyamoto K, Onami S, Yoshida T: Adrenocorticotropin-independent macronodular adrenocortical hyperplasia associated with multiple colon adenomas/carcinomas which showed a point mutation in the APC gene. Intern Med 1997 Aug;36(8):536–542.
82. Campbell KK, Baysdorfer C, Antonini S, Lacroix A: V1 vasopressin receptor sequence and expression in adrenal Cushing’s syndrome with aberrant response to vasopressin (abstract). 86th Meeting of the Endocrine Society, New Orleans, 2004, p 566.
83. Louiset E, Contesse V, Cartier D, Bertherat J, Duparc C, Barrande G, Groussin L, Vaudry H, Lefebvre H: Pharmacological profile and coupling mechanisms of illegitimate receptors in ACTH-independent macronodular bilateral adrenal hyperplasia causing Cushing’s syndrome (abstract). 86th Meeting of the Endocrine Society, New Orleans, 2004, p 564.
84. Mune T, Murase H, Yamakita N, Fukuda T, Murayama M, Miura A, Suwa T, Hanafusa J, Daido H, Morita H, Yasuda K: Eutopic overexpression of vasopressin V1a receptor in adrenocorticotropin-independent macronodular adrenal hyperplasia. J Clin Endocrinol Metab 2002 Dec;87(12):5706–5713. doi: 10.1210/jc.2002-020067
85. Beuschlein F, Reincke M, Karl M, Travis WD, Jaursch-Hancke C, Abdelhamid S, Chrousos GP, Allolio B: Clonal composition of human adrenocortical neoplasms. Cancer Res 1994 Sep;54(18):4927–4932.
86. Daidoh H, Morita H, Hanafusa J, Mune T, Murase H, Sato M, Shibata T, Suwa T, Ishizuka T, Yasuda K: In vivo and in vitro effects of AVP and V1a receptor antagonist on Cushing’s syndrome due to ACTH-independent bilateral macronodular adrenocortical hyperplasia. Clin Endocrinol (Oxf) 1998 Sep;49(3):403–409. doi: 10.1046/j.1365-2265.1998.00490.x
87. Iida K, Kaji H, Matsumoto H, Okimura Y, Abe H, Fujisawa M, Kamidono S, Chihara K: Adrenocorticotrophin-independent macronodular adrenal hyperplasia in a patient with lysine vasopressin responsiveness but insensitivity to gastric inhibitory polypeptide. Clin Endocrinol (Oxf) 1997 Dec;47(6):739–745. doi: 10.1046/j.1365-2265.1997.3011151.x
88. Mircescu H, Jilwan J, N’Diaye N, Bourdeau I, Tremblay J, Hamet P, Lacroix A: Are ectopic or abnormal membrane hormone receptors frequently present in adrenal Cushing’s syndrome? J Clin Endocrinol Metab 2000 Oct;85(10):3531–3536.doi: 10.1210/jcem.85.10.6865
89. Perraudin V, Delarue C, de Keyzer Y, Bertagna X, Kuhn JM, Contesse V, Clauser E, Vaudry H: Vasopressin-responsive adrenocortical tumor in a mild Cushing’s syndrome: In vivo and in vitro studies. J Clin Endocrinol Metab 1995 Sep;80(9):2661–2667. doi: 10.1210/jcem.80.9.7673409
90. Pignatelli D, Rodrigues E, Barbosa AM, Medina JL: Cushing syndrome due to the ectopic expression of adrenergic receptors in the adrenal cortex. A case of ACTH independent macronodular adrenal hyperplasia (AIMAH) (abstract). 86th Meeting of the Endocrine Society, New Orleans, 2004, p 611.
91. Miyamura N, Tsutsumi A, Senokuchi H, Nakamaru K, Kawashima J, Sakai K, Taguchi T, Tokunaga H, Nishida K, Uehara M, Sakakida M, Araki E: A case of ACTH-independent macronodular adrenal hyperplasia: Simultaneous expression of several aberrant hormone receptors in the adrenal gland. Endocr J 2003 Jun;50(3):333–340. doi: 10.1507/endocrj.50.333
92. Segaloff DL, Ascoli M: The lutropin/choriogonadotropin receptor. 4 years later. Endocr Rev 1993 Jun;14(3):324–347. doi: 10.1210/edrv-14-3-324
93. Seron-Ferre M, Lawrence CC, Jaffe RB: Role of hCG in regulation of the fetal zone of the human fetal adrenal gland. J Clin Endocrinol Metab 1978 May;46(5):834–837. doi: 10.1210/jcem-46-5-834
94. N’Diaye N, Cartier D, Bourdeau I, Tremblay J, Hamet P, Lefebvre H, Lacroix A: Characterization of aberrant LH/hCG and serotonin 5-HT4 receptors in adrenal Cushing’s syndrome (abstract). 83rd Annual Meeting of the Endocrine Society, Denver, 2001, p 235.
95. Bertherat J, Barrande G, Lefebvre H, Raffin-Sanson ML, Bertagna X: Systematic screening confirms that illicit membrane receptors are frequent and often multiple in bilateral ACTH-independent macronodular adrenal hyperplasia (AIMAH) (abstract). 83rd Annual Meeting of the Endocrine Society, Denver, 2001, p 233.
96. Lefebvre H, Contesse V, Delarue C, Vaudry H, Kuhn JM: Serotonergic regulation of adrenocortical function. Horm Metab Res 1998 Jun-Jul;30(6-7):398–403. doi: 10.1055/s-2007-978904
97. Mannelli M, Ferruzzi P, Luciani P, Crescioli C, Buci L, Corona G, Serio M, Peri A: Cushing’s syndrome in a patient with bilateral macronodular adrenal hyperplasia responding to cisapride: An in vivo and in vitro study. J Clin Endocrinol Metab 2003 Oct;88(10):4616–4622. doi: 10.1210/jc.2002-021949
98. Hayashi Y, Takeda Y, Kaneko K, Koyama H, Aiba M, Ikeda U, Shimada K: A case of Cushing’s syndrome due to ACTH-independent bilateral macronodular hyperplasia associated with excessive secretion of mineralocorticoids. Endocr J 1998 Aug;45(4):485–491. https://doi.org/10.1507/endocrj.45.485
99. Bertherat J, Contesse V, Louiset E, Barrande G, Duparc C, Groussin L, Emy P, Bertagna X, Kuhn JM, Vaudry H, Lefebvre H: Abnormal sensitivity of the adrenocortical tissue to multiple stimuli in ACTH-independent macronodular adrenal hyperplasia (AIMAH) causing Cushing’s syndrome: In vivo and in vitro studies (abstract). 86th Meeting of the Endocrine Society, New Orleans, 2004, p 562.
100. Slieker LJ, Sloop KW, Surface PL, Kriauciunas A, LaQuier F, Manetta J, Bue-Valleskey J, Stephens TW: Regulation of expression of ob mRNA and protein by glucocorticoids and cAMP. J Biol Chem 1996 Mar;271(10):5301–5304. doi: 10.1074/jbc.271.10.5301
101. Glasow A, Bornstein SR, Chrousos GP, Brown JW, Scherbaum WA: Detection of Ob-receptor in human adrenal neoplasms and effect of leptin on adrenal cell proliferation. Horm Metab Res 1999 Apr;31(4):247–251. doi: 10.1055/s-2007-978726
102. Pralong FP, Roduit R, Waeber G, Castillo E, Mosimann F, Thorens B, Gaillard RC: Leptin inhibits directly glucocorticoid secretion by normal human and rat adrenal gland. Endocrinology 1998 Oct;139(10):4264–4268. doi: 10.1210/endo.139.10.6254
103. Makino S, Hashimoto K, Sugiyama M, Hirasawa R, Takao T, Ota Z, Saegusa M, Ohashi T, Omori H: Cushing’s syndrome due to huge nodular adrenocortical hyperplasia with fluctuation of urinary 17-OHCS excretion. Endocrinol Jpn 1989 Oct;36(5):655–663.
104. Hashimoto K, Kawada Y, Murakami K, Hattori T, Suemaru S, Kageyama J, Ota Z, Hayata S, Ohashi T, Omori H: Cortisol responsiveness to insulin-induced hypoglycemia in Cushing’s syndrome with huge nodular adrenocortical hyperplasia. Endocrinol Jpn 1986 Aug;33(4):479–487. https://doi.org/10.1507/endocrj1954.33.479
105. Lacroix A, Baldacchino V, Bourdeau I, Hamet P, Tremblay J: Cushing’s syndrome variants secondary to aberrant hormone receptors. Trends Endocrinol Metab 2004 Oct;15(8):375–382. doi: 10.1016/j.tem.2004.08.007
106. Willenberg HS, Stratakis CA, Marx C, Ehrhart-Bornstein M, Chrousos GP, Bornstein SR: Aberrant interleukin-1 receptors in a cortisol-secreting adrenal adenoma causing Cushing’s syndrome. N Engl J Med 1998 Jul 3;339(1):27–31. doi: 10.1056/NEJM199807023390105
107. Burgess JR, Harle RA, Tucker P, et al. Adrenal lesions in a large kindred with multiple endocrine neoplasia type 1. Arch Surg. 1996 Jul;131(7):699–702. doi:10.1001/archsurg.1996.01430190021006 [PubMed]
108. Assie G, Libe R, Espiard S, et al. ARMC5 mutations in macronodular adrenal hyperplasia with Cushing's syndrome. N Engl J Med. 2013;369:2105–2114. doi: 10.1056/NEJMoa1304603 [PMC free article] [PubMed] [Cross Ref]
109. Fabio R, et al. Macronodular Adrenal Hyperplasia due to Mutations in an Armadillo Repeat Containing 5 (ARMC5) Gene: A Clinical and Genetic Investigation J Clin Endocrinol Metab. 2014 Jun; 99(6): E1113–E1119. doi: 10.1210/jc.2013-4280
110. Faucz FR, Zilbermint M, Lodish MB, et al. Macronodular adrenal hyperplasia due to mutations in an armadillo repeat containing 5 (ARMC5) gene: a clinical and genetic investigation. J Clin Endocrinol Metab. 2014;99:E1113–E1119. Doi: 10.1210/jc.2013-4280 [PMC free article][PubMed] [Cross Ref]
111. Alencar GA, Lerario AM, Nishi MY, et al. ARMC5 mutations are a frequent cause of primary macronodular adrenal hyperplasia. J Clin Endocrinol Metab. 2014 Aug;99(8):E1501–E1509. doi: 10.1210/jc.2013-4237 [PubMed] [Cross Ref]
112. Gagliardi L, Schreiber AW, Hahn CN, Feng J, Cranston T, Boon H, et al. ARMC5 mutations are common in familial bilateral macronodular adrenal hyperplasia. J Clin Endocrinol Metab 2014;99:E1784–92. doi: 10.1210/jc.2014-1265 [PubMed] [Cross Ref]
113. Elbelt U, Trovato A, Kloth M, et al. Molecular and clinical evidence for an ARMC5 tumor syndrome: concurrent inactivating germline and somatic mutations are associated with both primary macronodular adrenal hyperplasia and meningioma. J Clin Endocrinol Metab. 2015;100:E119–E128. doi: 10.1210/jc.2014-2648 [PMC free article] [PubMed] [Cross Ref]
114. Antonini SR, Baldacchino V, Tremblay J, Hamet P, Lacroix A. Expression of ACTH receptor pathway genes in glucose-dependent insulinotrophic peptide (GIP)-dependent Cushing’s syndrome. Clin Endocrinol (Oxf) 2006;64:29–36. doi: 10.1111/j.1365-2265.2005.02411.x [PubMed] [Cross Ref]
115. Espiard S, Drougat L, Libe R, Assie G, Perlemoine K, Guignat L, et al. ARMC5 mutations in a large cohort of primary macronodular adrenal hyperplasia: clinical and functional consequences. J Clin Endocrinol Metab 2015. Jun; 100(6): E926–E935. doi: 10.1210/jc.2014-4204 [PMC free article] [PubMed] [Cross Ref]
116. Zilbermint M, Xekouki P, Faucz FR, Berthon A, Gkourogianni A, Helene Schernthaner-Reiter M, et al. Primary aldosteronism and ARMC5 variants. J Clin Endocrinol Metab (2015). doi: 10.1210/jc.2014-4167 [PMC free article] [PubMed] [Cross Ref]
117. Xu Y, Rui W, Qi Y, Zhang C, Zhao J, Wang X, Wu Y, Zhu Q, Shen Z, Ning G, Zhu Y. The role of unilateral adrenalectomy in corticotropin-independent bilateral adrenocortical hyperplasias. World J Surg. 2013;37(7):1626–1632. doi: 10.1007/s00268-013-2059-9. [PubMed] [Cross Ref]
118. Tokumoto M, et al. A case of Adrenocoricotrophic hormone -independent bilateral adrenocortical macronodular hyperplasia concomitant with primary aldosteronism. BMC Surg. 2017; 17: 97. doi: 10.1186/s12893-017-0293-z
119. Doppman JL, Chrousos GP, Papanicolaou DA, Stratakis CA, Alexander HR, Nieman LK. Adrenocorticotropin-independent macronodular adrenal hyperplasia: an uncommon cause of primary adrenal hypercortisolism. Radiology. 2000;216:797–802. doi: 10.1148/radiology.216.3.r00au40797.[PubMed] [Cross Ref]
120. Mellinger RC, Smith RW Jr Studies of the adrenal hyperfunction in 2 patients with atypical Cushing’s syndrome. J Clin Endocrinol Metab. 1956 Mar;16(3):350–366. doi: 10.1210/jcem-16-3-350 [PubMed]
121. Sarlis NJ, Chrousos GP, Doppman JL, et al. Primary pigmented nodular adrenocortical disease: reevaluation of a patient with carney complex 27 years after unilateral adrenalectomy. J Clin Endocrinol Metab. 1997 Apr;82(4):1274–1278. doi: 10.1210/jcem.82.4.3857 [PubMed]
122. Gomez Muguruza MT, Chrousos GP. Periodic Cushing syndrome in a short boy: usefulness of the ovine corticotropin releasing hormone test. J Pediatr. 1989 Aug;115(2):270–273. doi: https://doi.org/10.1016/S0022-3476(89)80081-2 [PubMed]
123. Sarlis NJ, Papanicolaou DA, Chrousos GP, Stratakis CA. Paradoxical increase ofurinary free cortisol and 17-hydroxysteroids to dexamethasone during Liddle’s test: a diagnostic test for primary pigmented adrenocortical disease. Proceedings of the 79th Annual Meeting of the Endocrine Society in Minneapolis, MN; Endocrine Society Press; 1997. p. 303. [Abstract P2 – 76] 
124. Caticha O, Odell WD, Wilson DE, et al. Estradiol stimulates cortisol production by adrenal cells in estrogen-dependent primary adrenocortical nodular dysplasia. J Clin Endocrinol Metab. 1993 Aug;77(2):494–497. doi: 10.1210/jcem.77.2.8345057 [PubMed]
125. Carney JA, Gordon H, Carpenter PC, et al. The complex of myxomas, spotty pigmentation, and endocrine overactivity. Medicine (Baltimore) 1985 Jul;64(4):270–283. [PubMed]
126. Ohashi A, Yamada Y, Sakaguchi K, Inoue T, Kubo M, Fushimi H: A natural history of adrenocorticotropin-independent bilateral adrenal macronodular hyperplasia (AIMAH) from preclinical to clinically overt Cushing’s syndrome. Endocr J 2001 Oct;48(6):677–683.
127. Sasao T, Itoh N, Sato Y, et al. Subclinical Cushing syndrome due to adrenocorticotropic hormone-independent macronodular adrenocortical hyperplasia: changes in plasma cortisol levels during long-term follow-up. Urology. 2000;55:145. http://dx.doi.org/10.1016/S0090-4295(99)00381-7. [PubMed]
128. Lee KT, Arnott RD, McLean CA, et al. Corticotropin-independent macronodular adrenal hyperplasia associated with insulinoma. Endocr Pract. 2011;17:e43–7. http://dx.doi.org/10.4158/EP10213.CR.[PubMed]
129. Yamada Y, Sakaguchi K, Inoue T, Kubo M, Fushimi H, Sekii K, Itatani H, Tsujimura T, Kameyama M: Preclinical Cushing’s syndrome due to adrenocorticotropin-independent bilateral adrenocortical macronodular hyperplasia with concurrent excess of gluco- and mineralocorticoids. Intern Med 1997 Sep;36(9):628–632. https://doi.org/10.2169/internalmedicine.36.628
130. Yared Z, Antonini S, Lacroix A: Macronodular adrenal hyperplasia with long-term primary hyperaldosteronism and recent cyclical Cushing’s syndrome with aberrant response of cortisol to serotonin agonist 5-HT4 R (abstract). 85th Meeting of the Endocrine Society, Philadelphia, 2003, p 445.
131. Malchoff CD, Rosa J, DeBold CR, Kozol RA, Ramsby GR, Page DL, Malchoff DM, Orth DN: Adrenocorticotropin-independent bilateral macronodular adrenal hyperplasia: An unusual cause of Cushing’s syndrome. J Clin Endocrinol Metab 1989 Apr;68(4):855–860. doi: 10.1210/jcem-68-4-855
132. Goodarzi MO, Dawson DW, Li X, Lei Z, Shintaku P, Rao CV, Van Herle AJ: Virilization in bilateral macronodular adrenal hyperplasia controlled by luteinizing hormone. J Clin Endocrinol Metab 2003 Jan;88(1):73–77. doi: 10.1210/jc.2002-021292
133. Wilmot Roussel H, Vezzosi D, Rizk-Rabin M, et al. Identification of gene expression profiles associated with cortisol secretion in adrenocortical adenomas. J Clin Endocrinol Metab. 2013;98(6):E1109–E1121. doi: 10.1210/jc.2012-4237 [PubMed]
134. Rone MB, Fan J, Papadopoulos V. Cholesterol transport in steroid biosynthesis: role of protein-protein interactions and implications in disease states. Biochim Biophys Acta. 2009 Jul;1791(7):646–658. doi: 10.1016/j.bbalip.2009.03.001. [PMC free article] [PubMed]
135. Burg JS, Espenshade PJ. Regulation of HMG-CoA reductase in mammals and yeast. Prog Lipid Res. 2011 Oct;50(4):403–410. doi: 10.1016/j.plipres.2011.07.002. [PMC free article] [PubMed]
136. Hauet T, Liu J, Li H, Gazouli M, Culty M, Papadopoulos V. PBR, StAR, and PKA: partners in cholesterol transport in steroidogenic cells. Endocr Res. 2002 Nov;28(4):395–401. [PubMed]
137. Borkowski AJ, Levin S, Delcroix C, Mahler A, Verhas V. Blood cholesterol and hydrocortisone production in man: quantitative aspects of the utilization of circulating cholesterol by the adrenals at rest and under adrenocorticotropin stimulation. J Clin Invest. 1967 May;46(5):797–811. doi: 10.1172/JCI105580 [PMC free article][PubMed]
138. Connelly MA, Williams DL. SR-BI and cholesterol uptake into steroidogenic cells. Trends Endocrinol Metab. 2003 Dec;14(10):467–472. https://doi.org/10.1016/j.tem.2003.10.002 [PubMed]
139. Brown MS, Kovanen PT, Goldstein JL. Receptor-mediated uptake of lipoprotein-cholesterol and its utilization for steroid synthesis in the adrenal cortex. Recent Prog Horm Res. 1979;35:215–257. [PubMed]
140. Illingworth DR, Alam NA, Lindsey S. Adrenocortical response to adrenocorticotropin in heterozygous familial hypercholesterolemia. J Clin Endocrinol Metab. 1984 Jan;58(1):206–211. doi: 10.1210/jcem-58-1-206 [PubMed]
141. Bochem AE, Holleboom AG, Romijn JA, et al. High density lipoprotein as a source of cholesterol for adrenal steroidogenesis: a study in individuals with low plasma HDL-C. J Lipid Res. 2013 Jun;54(6):1698–1704. doi: 10.1194/jlr.P033449 [PMC free article] [PubMed]
142. Hoekstra M, Korporaal SJ, van der Sluis RJ, et al. LCAT deficiency in mice is associated with a diminished adrenal glucocorticoid function. J Lipid Res. 2013 Feb;54(2):358–364. doi: 10.1194/jlr.M030080 [PMC free article][PubMed]
143. Schmitz G, Langmann T. Structure, function and regulation of the ABC1 gene product. Curr Opin Lipidol. 2001 Apr;12(2):129–140. [PubMed]
144. Clark BJ, Stocco DM. StAR-A tissue specific acute mediator of steroidogenesis. Trends Endocrinol Metab. 1996 Sep;7(7):227–233. [PubMed]
145. London Е, et al. Cholesterol Biosynthesis and Trafficking in Cortisol-Producing Lesions of the Adrenal Cortex. J Clin Endocrinol Metab. 2015 Oct; 100(10): 3660–3667. doi: 10.1210/jc.2015-2212
146. Azziz R, Chang WY, Stanczyk FZ, Woods K. Effect of bilateral oophorectomy on adrenocortical function in women with polycystic ovary syndrome. Fertil Steril. 2013 Feb;99(2):599–604. doi: 10.1016/j.fertnstert.2012.10.016 [PMC free article][PubMed]
147. Rosenfield RL, Mortensen M, Wroblewski K, Littlejohn E, Ehrmann DA. Determination of the source of androgen excess in functionally atypical polycystic ovary syndrome by a short dexamethasone androgen-suppression test and a low-dose ACTH test. Hum Reprod. 2011 Nov;26(11):3138–3146. doi: 10.1093/humrep/der291. [PMC free article][PubMed]
148. Azziz R, Black V, Hines GA, Fox LM, Boots LR. Adrenal androgen excess in the polycystic ovary syndrome: sensitivity and responsivity of the hypothalamic-pituitary-adrenal axis. J Clin Endocrinol Metab. 1998 Jul;83(7):2317–2323. doi: 10.1210/jcem.83.7.4948 [PubMed]
149. Stewart PM, Penn R, Holder R, Parton A, Ratcliffe JG, London DR. The hypothalamo-pituitary-adrenal axis across the normal menstrual cycle and in polycystic ovary syndrome. Clin Endocrinol (Oxf). 1993 Apr;38(4):387–391. doi: 10.1111/j.1365-2265.1993.tb00519.x [PubMed]
150. Lachelin GC, Barnett M, Hopper BR, Brink G, Yen SS. Adrenal function in normal women and women with the polycystic ovary syndrome. J Clin Endocrinol Metab. 1979 Dec;49(6):892–898. doi:10.1210/jcem-49-6-892 [PubMed]
151. Moran C, Reyna R, Boots LS, Azziz R. Adrenocortical hyperresponsiveness to corticotropin in polycystic ovary syndrome patients with adrenal androgen excess. Fertil Steril. 2004 Jan;81(1):126–131. doi: https://doi.org/10.1016/j.fertnstert.2003.07.008 [PubMed]
152. Azziz R, Bradley EL, Jr, Potter HD, Boots LR. Adrenal androgen excess in women: lack of a role for 17-hydroxylase and 17,20-lyase dysregulation. J Clin Endocrinol Metab. 1995 Feb;80(2):400–405. doi: 10.1210/jcem.80.2.7852496. [PubMed]
153. Kahsar-Miller M, Boots LR, Bartolucci A, Azziz R. Role of a CYP17 polymorphism in the regulation of circulating dehydroepiandrosterone sulfate levels in women with polycystic ovary syndrome. Fertil Steril. 2004 Oct;82(4):973–975. doi: 10.1016/j.fertnstert.2004.05.068. [PubMed]
154. Martens JW, Geller DH, Arlt W, et al. Enzymatic activities of P450c17 stably expressed in fibroblasts from patients with the polycystic ovary syndrome. J Clin Endocrinol Metab. 2000 Nov;85(11):4338–4346.doi:10.1210/jcem.85.11.6971. [PubMed]
155. Gambineri A,